Cantor Fitzgerald Brokers Lower Earnings Estimates for JSPR

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for Jasper Therapeutics in a report issued on Wednesday, May 14th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($4.52) per share for the year, down from their prior estimate of ($4.17). The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24).

Several other analysts have also weighed in on the company. UBS Group decreased their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, May 13th. Oppenheimer decreased their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Jasper Therapeutics in a report on Tuesday, March 11th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $62.22.

Jasper Therapeutics Trading Up 1.2%

Shares of NASDAQ:JSPR opened at $4.93 on Friday. Jasper Therapeutics has a 1-year low of $3.13 and a 1-year high of $26.84. The firm has a market capitalization of $74.06 million, a PE ratio of -1.04 and a beta of 2.74. The business’s 50 day moving average is $4.60 and its 200-day moving average is $10.93.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of JSPR. Barclays PLC lifted its position in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after buying an additional 12,308 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Jasper Therapeutics by 239.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,391 shares of the company’s stock worth $308,000 after buying an additional 11,567 shares during the period. Rhumbline Advisers lifted its position in shares of Jasper Therapeutics by 12.6% during the 4th quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock worth $316,000 after buying an additional 1,652 shares during the period. Simplify Asset Management Inc. bought a new position in shares of Jasper Therapeutics during the 4th quarter worth approximately $428,000. Finally, EntryPoint Capital LLC bought a new position in shares of Jasper Therapeutics during the 4th quarter worth approximately $223,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.